US Food and Drug Administration (FDA) approvals of oral small–molecule anticancer agents have substantially increased over the past 6 years. From 2013 to 2018, 35 new molecular entities received introductory indications, with 9 new drugs approved in 2018.1 These approvals bring progressively increasing prices, prompting greater scrutiny and evaluation of alternative treatment strategies using pharmacology and other data to improve value. Examples include reduced-dose abiraterone, 250 mg (with food), which demonstrated pharmacodynamic noninferiority when compared with 1000 mg (fasting).2 A trial of reduced-dose ibrutinib showed greater than 95% receptor occupancy across doses with commensurate chemokine reductions, prompting calls for larger trials to reduce costs and improve tolerability.3 Clinical pharmacology-based studies add value to cancer care, and there are additional opportunities to use other approaches to treatment such as changes in prescribing and dispensing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Harvey RD, Ratain MJ. A Cost-Focused Alternative Cancer Medication Dispensing Strategy—“Pack Splitting”. JAMA Oncol. 2019;5(12):1691–1692. doi:10.1001/jamaoncol.2019.4129
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.